Several lines of evidence support the concept that NK cells play an important role in control of hepatitis C virus (HCV) infection via cytokine secretion and cytotoxicity. IL-7 is a homeostatic cytokine with a role in T cell development, activation, proliferation, and cytokine secretion. The IL-7Ra chain [cluster of differentiation (CD) 
Introduction
HCV infection is present in ;170 million individuals worldwide, with 60-85% of acute infections leading to chronic infection [1] [2] [3] . HCV therapy has improved significantly in recent years, although the cost of IFN-free antiviral therapy remains a barrier for many [4] . Additionally, therapy itself is not anticipated to remove HCV from the population as a whole [5, 6] . For these reasons, a better understanding of the host immune response to HCV is sought to develop successful vaccine strategies.
Given overlapping modes of transmission, there is a significant proportion of HIV-infected persons coinfected with HCV [7] . Although HIV-associated morbidity and mortality have been reduced as a result of the use of ART, HCV infection is a cause of increased morbidity and mortality in HCV-HIV-coinfected individuals [8, 9] . Furthermore, HIV infection alters HCV disease pathogenesis, accelerating progression to cirrhosis and liver failure [10, 11] .
NK cells are important in immune control of HCV and HIV infections [12, 13] . HLA and killer Ig-like receptor repertoires have been associated with HCV infection outcome and also with rates of HIV disease progression [14] [15] [16] . NK cells are readily found in the blood, liver, and spleen and in lesser quantities in the lymph nodes and inflamed tissues [14] . NK cells are divided into 3 main subsets, based on expression of CD56 (neural cell adhesion molecule 1) and CD16 (FcgRIIIA): CD56   bright   , CD56   dim   ,  and CD56 neg NK cells [12, 17] . Whereas all NK cell subsets share an overlap of effector functions, each has distinct phenotypic and functional characteristics. CD56 neg NK cells make up ,5% of NK cells in the peripheral blood of healthy humans and have been demonstrated to expand in chronic HCV and HIV infections and be dysregulated, characterized by weak cytolytic activity and cytokine production [18] . CD56 dim NK cells are considered highly cytolytic, although capable of moderate cytokine release, and compose nearly 85% of all NK cells in peripheral blood [19] . Whereas CD56 bright NK cells contribute to 5-10% of NK cells in the blood [19] , they bear homing receptors that allow entry into sites of inflammation and infection, including secondary lymphoid tissue and the liver [20] . The CD56 bright subset is considered less mature than the CD56 dim and CD56 neg subsets and is less cytotoxic, yet is a major source of cytokine production [21, 22] . NK cells can contribute to viral control via cytokine and chemokine secretion and cytolytic function [14] . NK cells derived from subjects with chronic HCV infection have been shown to be polarized toward greater cytolytic function and lower IFN-g activity [23, 24] . Specifically, NK cell IFN-g production is reduced in chronic HCV and HIV infections [18] , and this is associated with an inability to clear HCV [24, 25] . CD56 bright NK cells help shape the adaptive immune response via polarizing cytokine secretion and through cell-cell interactions. Upon exposure to pathogen-associated molecular patterns, CD56 bright NK cells release predominantly IFN-g and TNF-a, which promote an antiviral T cell response [21, 22] . NK cells also promote DC maturation by IFN-g and TNF-a release, as well as by direct killing of immature DCs, a process known as DC editing [22] . CD56 bright NK cells have also been shown to regulate CD4 T cells directly [26] . Because of the multifaceted roles of NK cells, from immunoregulation to cytolysis of virally infected cells, a better understanding of how they are activated during chronic viral infection is likely to inform antiviral vaccine and treatment strategies.
IL-7 is produced by stromal cells in the bone marrow, thymus, lymph node, and liver. The IL-7R is composed of the common g chain (CD132) and the high-affinity a receptor (CD127) and signals through the JAK-STAT-5 and AKT pathways [27, 28] . Loss of CD127 expression on CD4 and CD8 T cells has been associated with the inability to resolve both acute and chronic HCV infection [29] . Additionally, CD127 expression on HCV-specific CD8 T cells is negatively correlated with HCV viral levels and positively correlated with intracellular IFN-g expression [29, 30] . Whereas it is known that CD127 is expressed on NK cells-predominantly on CD56 bright NK cells [31] -little is known about the role of IL-7 in regulating NK cell function during chronic HCV or HIV infections. Here, we evaluated IL-7-dependent NK cell effector function in subjects infected with HCV, HIV, or coinfected with both HCV and HIV. We found that IL-7 promotes CD56 bright NK cell activation, IFN-g release, and Ki67 induction, as well as NK cell cytolytic activity, which are selectively impaired upon the presence of chronic HCV or HIV infections. Together, these data support a role for IL-7-dependent NK cell effector function in control of chronic viral infection and highlight a novel, potential virally associated impairment of host immune surveillance.
MATERIALS AND METHODS

Study subjects
Thirty-four HCV-infected subjects (antibody positive $ 6 mo; HCV RNA positive, genotype 1), naive to therapy; 42 HCV-HIV-coinfected subjects; 25 HIV-infected subjects (HIV ELISA and Western positive, prior HIV RNA positive, HIV-1 RNA , 50 copies/ml on ART for at least 8 wk, HCV RNA negative, CD4 cell count . 200/mm 3 ); and 25 age range-matched UD were enrolled ( Table 1) . The HCV-HIV-coinfected subjects (HIV-1 RNA , 50 copies/ml on ART for at least 8 wk) met above criteria for HCV and HIV infection and were infected with genotype 1 HCV. Duration of HCV infection was estimated based on the first year of known intravenous drug use or blood transfusion before 1992. As a result of cell availability, not all assays were performed on all subjects. Sample size for each experiment is indicated. All subjects gave Institutional Review Boardapproved written, informed consent at either the Veterans Affairs Medical Center, University Hospitals of Cleveland, or at one of the AIDS Clinical Trials Group sites. AST, ALT, PLT, albumin, plasma HCV RNA, and plasma HIV RNA levels were determined at the corresponding clinical laboratory. The APRI was calculated as [(AST/upper limit of normal)/ PLT] 3 100 [32] .
Ex vivo NK cell CD127 expression
The following were used: cryopreserved PBMCs, freshly isolated PBMCs, or freshly isolated NK cells by negative bead selection method (Stemcell Technologies, Vancouver, BC, Canada); depleting CD3/CD4/CD14/CD19/ CD20/CD36/CD66b/CD123/HLA-DR/glycophorin A-expressing cells, median purity . 95%; or negative selection, followed by staining with CD3/14/ 19-Alexa Fluor 700, CD56-PE-Cy7, and CD16-FITC (BD Biosciences, San Jose, CA, USA), followed by flow cytometry-assisted cell sorting (FACSAria cell sorter; BD Biosciences) of CD3 ) were analyzed by viability LIVE/DEAD yellow dye (Thermo Fisher Scientific, Waltham, MA, USA). Lymphocytes were identified by forward-and side-scatter, and NK cell phenotype was assessed using the following mAb: anti-CD3/CD14/CD19-Alexa Fluor 700 (UCHT1, M5E2; BioLegend, San Diego, CA, USA), anti-CD7-PerCP-Cy5.5 (BD Biosciences), anti-CD56-PE-Cy7 (B159; BioLegend), anti-CD16-allophycocyanin-H7 (3G8; BD Biosciences), and anti-CD127-Brilliant Violet 421 (A019D5; BioLegend), or isotype controls. We compared freshly derived PBMCs with cryopreserved PBMCs to ensure that the freezing and thawing process did not alter NK cell subset frequency or CD127 surface expression (Supplemental Fig. 1A ). Flow cytometric data were acquired on a BD LSR II (BD Biosciences) and analyzed with FlowJo software (TreeStar, Ashland, OR, USA).
IL-7 induction of Ki67, BCL-2, IFN-g, and pSTAT-5
Fresh PBMCs (1 3 10 6 ) were cultured in the presence or absence of 10 ng/ml IL-7 or 500 U/ml IFN-a overnight. In some assays, IL- In vitro NK cell CD127, CD69, FasL, TRAIL, NKp30, NKG2A, and IFN-aR1 expression 
IL-7 and sCD127 ELISA
Serum was evaluated for IL-7 levels by ELISA (R&D Systems). A 96-well polystyrene plate was coated with 50 ml mouse anti-human CD127 (100 ng/ml; R&D Systems) in PBS overnight. The next day, the plate was washed (PBSTween) and blocked for 2 h at room temperature with PBS + 1% BSA. The plate was washed, and 50 ml serum or standards were incubated for 3 h at room temperature. After washing, the plate was incubated with 5 mg/ml biotin poly-goat anti-CD127 (R&D Systems) for 1 h at room temperature and then incubated with streptavidin-HRP. Reactions were developed with tetramethylbenzidine substrate, and results were obtained via a plate reader at 450 nm. Sample concentrations were extrapolated from standard curves of recombinant human CD127-Fc chimera, as described previously [33] .
ELISPOT assays
were plated with or without the presence of 10 ng/ml IL-7 (unless otherwise stated), IFN-a (500 U/ml), or IL-12 (1 ng/ml) in ELISPOT plates precoated with anti-IFN-g (human IFN-g mAb, clone 2G1; Thermo Fisher Scientific), TNF (TNF-3/4; MabTech, Nacka Strand, Sweden), or granzyme B (GB11; Bio-Rad Laboratories, Hercules, CA, USA) capture mAb, and cells were cultured for 20 h at 37°C. In some assays, IL-7-treated cells were cultured additionally with the wortmannin or pSTAT-5 inhibitor, as stated above. Secondary antibody was added, and spots were detected as described previously [34] . -Alexa Fluor 700 (UCHT1, M5E2; BioLegend), anti-CD56-PE-Cy7 (B159; BioLegend), and anti-CD16-allophycocyanin-H7 (3G8; BD Biosciences).
CD107a degranulation assay
NK cell cytolysis assay
Huh7.5 hepatoma cells were provided by Dr. Charles M. Rice (Apath, New York, NY, USA). The pJFH1 plasmid was provided by Dr. Takaji Wakita (Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan). Infectious JFH1 virus was prepared as described [35] . Huh7.5 cells (2 3 10 3 ) were plated, cultured for 1 d, and then infected with 1 multiplicity of infection of JFH1, 52 h before NK cell coculture. NK cells were isolated from PBMCs within 3 h of phlebotomy, as described above, and tested for cytolytic activity against JFH1-infected or uninfected Huh7.5 or K562 cells, directly or after pretreatment with 10 ng/ml IL-7 (unless otherwise stated), 500 U/ml IFN-a2a, or complete RPMI medium for 16 h and washed. NK cells (5 3 10 4 ) were added to HCV-infected or uninfected HuH 7.5 or K562 cells (1 3 10 4 at time of coculture) to achieve an E:T ratio of 5:1 for 5 h. NK-Huh7.5 cell coculture supernatant was analyzed by M30 ELISA (Diapharma, West Chester, OH, USA), which detects Huh cell caspase-cleaved cytokeratin 18. NK-K562 cell coculture supernatant was analyzed by an LDH release assay. Spontaneous effector and target and maximal lytic reagent-induced target cell death were evaluated in control wells. 
Statistical analysis
Statistical analyses were performed with Prism software (GraphPad Software, La Jolla, CA, USA), version 5.04. We used Mann-Whitney U-test for two-way comparisons of continuous variables between groups. We used Wilcoxon signed-rank-related samples test for nonparametric comparison of related, continuous variables within groups and Spearman rank correlation coefficient to analyze associations between continuous variables. All tests of significance were two sided, and P , 0.05 was considered significant.
RESULTS
CD56
bright NK cell CD127 expression is negatively associated with plasma HCV level
We first analyzed cryopreserved PBMCs in each study group for NK cell subset frequency, characterizing NK cells based on surface expression of CD56 and CD16 on lymphocyte-gated cells that were viable and CD7 1A) . There was no difference in total NK cell frequency comparing chronic HCV, HIV, or HCV-HIV-coinfected subjects with UD. Whereas there was no altered frequency of CD56 dim or CD56 bright NK cells in HCV, HIV, or HCV-HIV-coinfected subjects, we did observe an increased frequency of CD56 neg NK cells in HIV-infected subjects (P = 0.02; not shown) and a trend toward an increase in HCV-HIV-coinfected subjects (P = 0.12). As CD127 is the cellular receptor for IL-7 and also plays an important role in modulating IL-7 activity in plasma [28] , we next measured CD127 expression on NK cell subsets in samples from each group. CD127 was most abundantly expressed on the CD56 bright NK subset (Fig. 1A) , consistent with previous literature [31] . Comparing groups, CD56
bright NK subset CD127 expression was similar, comparing HCV monoinfection with UD (Supplemental Fig. 1B) . Notably, however, the proportion of CD56 bright NK cells expressing CD127, but not MFI of CD127 expression, was negatively correlated with plasma HCV levels in HCVmonoinfected subjects (r = 20.400, P = 0.020; Fig. 1B ) and in HCV-HIV-coinfected subjects (r = 20.340, P = 0.037; Fig. 1C ). This negative relationship was also observed upon secondary analysis of purified NK cells from HCV-monoinfected subjects (r = 20.500, P = 0.030; Supplemental Fig. 1C) .
In addition to downstream signaling, IL-7 binding to CD127 can result in lower cell surface CD127 expression [28] . Whether the negative association between CD56 bright NK cell CD127 expression and HCV level was attributable to serum IL-7 levels was next evaluated. Serum IL-7 was lower in HCV-monoinfected subjects compared with UD (P = 0.040; Fig. 1D ), consistent with previous literature [36] . In contrast, HIV-infected subjects had greater serum levels of IL-7 than UD (P = 0.014), and HCV-HIVcoinfected subjects had higher serum IL-7 levels than HCVmonoinfected subjects (P = 0.018; Fig. 1D ). There was a trend toward an inverse association between serum IL-7 level and CD4 count in HIV mono-and HCV-HIV-coinfected subjects (n = 10, r = 20.576, P = 0.088 and n = 9, r = 20.583, P = 0.108, respectively), consistent with prior literature [37] . There was no association between serum IL-7 levels and HCV levels or CD127 expression on CD56 bright NK cells.
IL-7 induces CD56 bright NK cell activation, and this is impaired in HIV infection
Given that expression of CD127 on CD56 bright NK cells correlated negatively with plasma HCV level, we considered the possibility that IL-7 signaling plays a role in NK cell control of HCV infection. Therefore, we next sought to determine directly the effect of IL-7 on NK cell activation in ex vivo assays. Purified NK cells of UD (n = 20), uncontrolled HCV (n = 20), virally suppressed HIV (n = 16), and HCV-HIV-coinfected (n = 13) subjects were cultured in the presence or absence of IL-7, IFN-a, or IL-12 overnight. CD69, NKp30, NKG2A, and IFN-aR1 expression was measured on each NK cell subset as indicators of NK cell activation and IFN-a response capacity. As the doseresponse relationship of IL-7 on NK cell activation and the expression of these surface markers were unknown, we carried out a concentration curve titration of IL-7, ranging from 0.01 to 100 ng/ml. Whereas there was no effect of IL-7 on NK cell subset expression of NKp30, NKG2A, or IFN-aR1, IL-7 did induce CD56 bright NK cell CD69 expression in a dose-dependent manner (Supplemental Fig. 2A ). The effect of IL-7 on NK cell activation plateaued at 10 ng/ml IL-7. At 10 ng/ml IL-7, we observed significant enhancement of CD56 bright NK cell CD69 expression in UD, measured both as the proportion of cells expressing CD69 and as MFI ( Fig. 2A and B ; P = 0.020, 0.040, respectively). There was no significant up-regulation of CD69 expression upon IL-7 stimulation of CD56 dim (P = 0.430) or CD56 neg NK cell (P = 0.831) subsets or on flow-sorted CD56 dim NK cells of UD (n = 3; not shown). A similar pattern was observed with NK cells from HCV-infected subjects, with significant IL-7-mediated enhancement of CD56 bright NK cell CD69 expression (P = 0.008, P = 0.002; Supplemental Fig. 2B and C ), but not with NK cells from HIV or HCV-HIV-infected subjects. Additionally, IFN-a enhanced the expression of CD69 on CD56 neg and CD56 dim NK cells of UD ( Fig. 2A) and HCV-infected subjects, as did IL-12 (not shown). We did not observe up-regulation of CD69 expression in CD56 bright NK cells of HIV (n = 7)-infected subjects in response to IFN-a (Supplemental Fig. 2C ) or in CD56 neg and CD56 dim NK cells of this cohort. Upon costimulation with IL-7 and IFN-a, we observed an additive effect of each cytokine on CD56 bright NK cell CD69 expression in samples from UD (P = 0.020; Fig. 2A and C). This combined effect of IL-7 and IFN-a was not above that induced by IFN-a alone in HCV (n = 7)-and HIV (n = 6)-infected subjects. We next examined the effect of IL-7 on NK cell surface expression of other known activating and inhibitory receptors (PD-1, NKG2C, NKG2D, NKp44, and NKp46) on cells of UD (n = 5 IL-7 induces NK cell IFN-g production in uninfected and HCV-and HIV-infected subjects, and this ex vivo activity is associated with CD127 expression
Previous findings demonstrate that IL-7 can promote CD56 bright NK cell IFN-g production in uninfected control subject samples and those of patients with multiple sclerosis [38] . Here, we extend these findings to determine the effect of IL-7 on NK cell IFN-g and TNF-a expression during chronic viral infection. IL-7 promoted purified NK cell IFN-g release with a dose-response curve similarly to the pattern seen for CD69 up-regulation, plateauing at 10 ng/ml (Fig. 3A) . We also observed an increase in NK cell TNF-a release upon IL-7 stimulation of samples from HCV-monoinfected subjects (P = 0.030; not shown). IL-7 induced NK cell IFN-g release from samples of UD (n = 20, P , 0.0001; Fig. 3B ), and this effect was also observed in HCV (n = 20, P , 0.0001)-, HIV (n = 20, P = 0.0015)-, and HIV-HCV (n = 15, P = 0.0005)-infected subjects (Fig. 3B) . The magnitude of IL-7-induced IFN-g from NK cells did not differ among groups. In contrast, the IFN-a-and IL-12-induced NK cell IFN-g release was impaired in samples from HCV-and HIV-infected and HCV-HIV-coinfected subjects (not shown), consistent with previous findings [39] . Consistent with the additive effect of IL-7 and IFNa on CD56 bright NK cell CD69 up-regulation, there was an additive induction of IFN-g upon culture with these two cytokines, with samples from UD (P = 0.04; Fig. 3C ), but not in HCV-or HIV-infected subjects (not shown).
To evaluate whether IL-7 signaling may play a role in NK cellmediated control of HCV, we next examined the baseline CD56 bright NK cell CD127 expression in relation to IL-7-induced IFN-g. There was a positive correlation between CD127 expression and IL-7-mediated bulk NK cell IFN-g release in UD (r = 0.560, P = 0.030) and HCV-monoinfected subjects (r = 0.560, P = 0.020; Supplemental Fig. 3 ) but not in HIV-infected or HCV-HIV-coinfected subjects. Additionally, we observed a weak negative trend toward a relationship between IL-7-induced NK cell IFN-g release and HCV level in HCV-monoinfected subjects (r = 20.370, P = 0.120; not shown), supporting a possible role for IL-7-dependent NK cell IFN-g in control of HCV. To confirm the IL-7-induced NK cell IFN-g release using another method, we analyzed NK cell subset IFN-g expression by intracellular staining and found that IL-7, at 10 ng/ml, indeed induced CD56 bright NK cell intracellular IFN-g production in UD subjects, and this remained intact in samples from HCV-, HIV-, and HIV-HCVinfected subjects (Fig. 3D) . We also cultured flow-sorted CD56 dim NK cells with or without IL-7 and observed no IL-7-mediated IFN-g release, further supporting the activity localized to the CD56 bright cells (not shown).
IL-7-dependent NK cell survival and cell cycling are impaired in HCV and HIV infections
Previous findings have shown that IL-7 promotes CD56 bright NK cell survival via up-regulation of BCL-2 [31] and induces cell cycling [38] . Whether this activity is altered during chronic viral infection is unknown. We first examined the effect of IL-7 on NK cell subset proportions over the time course of purified NK cell cultures. IL-7 tended to increase the proportion of NK cells in the CD56 bright NK cell subset (P = 0.100) and reduce the proportion of CD56 dim NK cells (P , 0.0001; Supplemental Fig. 4A ) in overnight cultures. There was no effect of IL-7 on CD56 neg NK subset proportion in these same cultures. In HIV-infected and HCV-HIV-coinfected subjects, there was a similar effect of IL-7 on the proportion of the CD56 bright NK cell subset (P = 0.041, P = 0.042, respectively; Supplemental 4C ).The effect of IL-7 on NK cell subset distribution in overnight cultures was muted in the presence of HCV infection, with no increase in the proportion of NK cells in the CD56 bright NK cells nor any effect on the CD56 dim or CD56 neg NK cell subsets (Supplemental Fig. 4B ).
To examine cell cycling and resistance to cell death, freshly obtained PBMCs from UD (n = 12) and HCV (n = 11)-, HIV (n = 12)-, and HIV-HCV (n = 8)-coinfected subjects were cultured in the presence or absence of IL-7 (10 ng/ml) overnight, followed by intracellular staining for BCL-2 and Ki67. IL-7 induced a modest but significant increase in BCL-2 expression in CD56 bright NK cells of UD (P = 0.050). We also observed increased Ki67 expression in CD56 bright NK cells of UD cultured with IL-7 (P = 0.020; Fig. 4) . These results are consistent with previous literature [31, 38] . There was no detectable effect on BCL-2 or Ki67 expression in the CD56 dim or CD56 neg NK cell subsets. IL-7-induced CD56 bright NK cell BCL-2 expression tended to be lower in HCV-monoinfected subjects (P = 0.070; Fig. 4A and C) , and IL-7-induced cycling (Ki67 expression) was lower in HCV-, HIV-, and HIV-HCV-infected subject samples compared with UD (P = 0.070, P = 0.030, and P = 0.004, respectively; Fig. 4B and D) . These results indicate that IL-7-induced NK cell cycling is impaired in direct ex vivo analysis of samples from HCV-and HIV-infected persons.
IL-7-induced NK cell degranulation is intact during HCV and HIV infection, but IL-7-enhanced NK cell killing of K562 targets is impaired
Cytotoxicity is a vital antiviral NK cell effector function that can occur through multiple mechanisms. Previous studies have shown that IL-7 can enhance CD56 bright NK cell CD107a expression [38] . Therefore, we measured NK cell subset upregulation of CD107a, a degranulation marker, in purified NK cells after culture with K562 target cells, in the presence or absence of IL-7 or IFN-a. In samples from UD, we observed significant IL-7-mediated enhancement of CD56 bright NK cell CD107a expression above that induced by K562 target cells (n = 10, P = 0.0004; Fig. 5A and B) . There was no effect of IL-7 on CD107a expression in CD56 dim or CD56 neg NK cell subsets in contrast to IFN-a treatment, which induced CD107a expression on all NK cell subsets (Fig. 5A ). This IL-7-mediated enhancement of CD56 bright NK cell degranulation was also seen in samples from HCV-infected subjects (n = 10, P = 0.0137), as well as HIV-infected subjects (n = 8, P = 0.016; Fig.  5B) . In a limited analysis of a small number of HCV-HIVcoinfected subjects (n = 3), we observed a similar pattern (Fig.  5B) . With the comparison of the magnitude of IL-7-induced CD56 bright NK cell CD107a expression, we observed no significant differences among groups, indicating that IL-7-mediated NK cell degranulation is likely intact in both chronic viral infections.
To determine further the ability of IL-7 to promote NK cell cytotoxicity, we analyzed purified NK cell granzyme B release using ELISPOT. Upon overnight culture, we observed IL-7-induced NK cell granzyme B release in samples from UD (n = 18, P = 0.0008). Spontaneous NK cell granzyme B release was heightened in HCV-infected subjects compared with that of UD (P = 0.020; Fig. 5C ). Nevertheless, IL-7-induced NK cell granzyme B release was intact in HCV subjects (n = 17, P = 0.0004, Fig. 5C ). However, the IL-7-induced granzyme B release was impaired in NK cells from HIV-infected and HIV-HCV-coinfected subjects (Fig. 5C) .
TRAIL is known to mediate cytotoxicity [23] . Therefore, we next evaluated the ability of IL-7 and IFN-a to induce NK cell subset surface expression of TRAIL after overnight stimulation. In all patient groups, there was no effect of IL-7 on CD56 dim or CD56 neg NK cell TRAIL expression, whereas there was an observed effect of IFN-a on TRAIL expression in the same NK cell subsets (Fig. 5D ). In contrast, there was a significant increase of CD56 bright NK cell TRAIL expression upon IL-7 stimulation in UD and HCV-infected donors (n = 10, P = 0.008; n = 10, P = 0.008, Fig. 5D ). The magnitude of IL-7-induced TRAIL expression was significantly lower than that induced by IFN-a in UD (n = 10, P = 0.030; Fig. 5D ). In a smaller sample set of HIV-infected (n = 5) subjects, we saw a similar pattern with moderate IL-7-induced CD56 bright NK cell TRAIL expression (P = 0.125; Fig. 5D ). NK cells can lyse Huh7.5 cells via IFNa-induced TRAIL [23] . To investigate if IL-7 facilitates NK cell cytotoxicity, potentially via TRAIL, we cultured purified bulk NK cells pretreated with IL-7 or IFN-a with Huh7.5 target cells, with or without HCV JFH1 infection. IL-7 did not induce bulk NK cell lysis of JFH1-infected Huh7.5 cells, whereas NK cells stimulated with IFN-a did tend to do so (n = 5, P = 0.156; Supplemental Fig. 5 ). Together, these results indicate that whereas IL-7 increases CD56 bright NK cell TRAIL expression, the enhanced expression is not sufficient to promote TRAIL-dependent cytotoxicity in the in vitro system used here. Notably, a previous report has shown that IL-7 promotes NK cell cytolytic activity via FasL-Fas interactions [40] . We did observe an increase in FasL (CD95 ligand) expression on
CD56
bright NK cells upon IL-7 stimulation in both UD and HCVinfected subject samples (n = 10, P = 0.008; n = 10, P = 0.078; Fig. 5E ). However, this was less clear in a smaller number of 1 UD) ; UD, n = 8; HCV, n = 9. NK cell cytolysis of K562 cells was measured by LDH assay with UD (n = 10; F). UD (n = 10), HCV (n = 10), HIV (n = 6), and HCV-HIV (n = 2); results depicted as frequency of K562 lysis above medium-alone conditions (F). Means 6 SEM shown. Mann-Whitney U test was peformed for two-way comparisons of continuous variables between groups. We used Wilcoxon signed-rank-related samples test for nonparametric comparison of related continuous variables within groups.
HIV-infected subject samples (n = 5; Fig. 5E ). IFN-a stimulation also enhanced CD56 bright NK cell FasL expression in samples from UD (n = 6, P = 0.030). In contrast to the effects on TRAIL expression, there was no significant difference in magnitude of IL-7-and IFN-a-mediated FasL up-regulation in any of the subject groups (Fig. 5E) or any difference in IL-7 or IFN-a induction of FasL on NK cells across subject groups. Next, we cultured NK cells with K562 cells, which we confirmed were susceptible to FasL-mediated cytolysis using a FasL agonist (not shown). Indeed, NK cell lysis of K562 target cells was enhanced in the presence of IL-7 (n = 10, P = 0.039; Fig. 5F ). The data here suggest that IL-7-mediated enhancement of NK cell lysis of K562 target cells may be impaired in samples from HCV-and HIV-infected and HIV-HCV-coinfected subjects (P = 0.11; Fig. 5F ).
IL-7-induced NK cell signaling is impaired in chronic HCV and HIV infection yet restored after HCV clearance
The impairments in IL-7-mediated NK cell survival, activation, and cytolytic activity in HCV and HIV infections may be attributable to changes in IL-7 signaling. Therefore, we next inquired if there were overall impairments in proximal IL-7 signaling in these chronic viral infections. IL-7 signaling requires down-regulation of CD127 surface expression and its subsequent internalization [28] . Therefore, we first analyzed NK cell subset cell surface CD127 expression after overnight culture with IL-7. Compared with UD (n = 16), we observed significantly less downregulation of CD127 surface expression on the CD56 bright NK cell subset in response to IL-7 stimulation in HCV (n = 18, P = 0.02)-and HIV (n = 13, P = 0.007)-infected and HIV-HCV-coinfected (n = 12, P = 0.009) subject samples (Fig. 6A) . CD127 surface down-regulation and internalization in response to IL-7 are followed by pSTAT-5, and this has been shown to be impaired in T cells of HIV-infected subjects [41] . We hypothesized that the impairments in IL-7-mediated NK cell activities in virus-infected subjects were a result of attenuated IL-7 signaling. At 15 min of IL-7 stimulation, pSTAT-5 was minimal but detectable in CD56 bright NK cells of UD, whereas this did not occur in HCV-or HIV-infected or HIV-HCV-coinfected subjects (not shown). We further investigated the effects of IL-7 on CD56 bright NK cell pSTAT-5 after 1 d of culture (Fig. 6B ) among the different patient groups. pSTAT-5 in CD56
bright NK cells in response to IL-7 was impaired in HCV-and HIV-infected and HIV-HCV-coinfected subjects (P , 0.0001, P = 0.003, and P = 0.0001; Fig. 6C ).
As IL-7-mediated NK cell IFN-g release remained intact in infected subjects (Fig. 3C) , we next investigated the extent to which CD127 signaling relied on another transcription factor, AKT. There was no detectable pAKT in any NK cell subset after 1 d of culture with IL-7 (not shown). At d 3, there was a trend toward IL-7-mediated pAKT in the CD56 bright NK cell subset of UD (P = 0.18) and HCV-infected subjects (n = 5 each, P = 0.12), as well as of 1 HIV-infected subject (Supplemental Fig. 6A and B) . In a small sample set of UD (n = 3), we evaluated the effect of blocking AKT versus STAT-5 on IL-7-mediated NK cell functions. Inhibition of STAT-5 led to impaired IL-7-mediated CD56 bright NK cell BCL-2 bright NK cell pSTAT-5 fold change compared with medium-alone treatment within UD (n = 10), HCV (n = 11), HIV (n = 9) and HIV-HCV (n = 9) subjects (C). IL-7 induced CD56 bright NK cell pSTAT-5 expression (above medium-alone conditions) before and after achieving SVR response upon HCV therapy (D). Means 6 SEM shown. Mann-Whitney U test was performed for two-way comparisons of continuous variables between groups. enhancement (not shown), as well as reduced TRAIL induction (Supplemental Fig. 6C ). When AKT was blocked, IL-7-induced CD56 bright NK cell FasL expression was minimized (Supplemental Fig. 6C ). IL-7-induced NK cell IFN-g release was assessed by ELISPOT in the presence or absence of STAT-5 or AKT inhibitors. Interestingly, inhibition of STAT-5 or AKT impaired IL-7-induced NK cell IFN-g release (Supplemental Fig. 6D ). This suggests that IL-7-induced NK cell IFN-g release relies on STAT-5 and AKT.
To determine the durability of the effect of HCV infection on NK cell CD127 signaling, we compared IL-7-mediated CD56 bright NK cell pSTAT-5 in HCV-infected subjects before and after achieving SVR with IFN-free, direct-acting antiviral therapy. The defective, IL-7-induced pSTAT-5 before therapy recovered 6 mo after institution of therapy and clearance of the virus and reached a level similar in magnitude to that in UD (Fig. 6D) . These results are consistent with a reversible effect of HCV on proximal IL-7 signaling in NK cells.
DISCUSSION
Here, we show that CD56 bright NK cell CD127 expression is negatively associated with plasma HCV level in both HCV monoinfection and HIV-HCV coinfection. This negative correlation may suggest that HCV infection exerts negative influence on CD127 expression. However, as CD56 bright NK cell CD127 expression is not lower in HCV-monoinfected or HCV-HIVcoinfected subjects compared with UD, we find this to be unlikely. Alternatively, whereas other possibilities exist, this association may be consistent with a role of IL-7/CD127 signaling on NK cell antiviral functions, contributing to control of HCV.
CD127 is most abundantly expressed on the CD56 bright subset of NK cells [31] . In the liver, NK cells comprise between 30 and 50% of all lymphocytes [42] and have a greater proportion of CD56 bright NK cells than found in the peripheral blood, in some subjects making up ;50% of hepatic NK cells [43, 44] . NK cells in the liver are characterized by production of polarizing cytokines, such as IFN-g and TNF-a [42] . Importantly, in the case of viral infection, IL-7 supports a strong Th1-type immune response by induction of IFN-g and IL-2 production [37] . CD8 T cell CD127 expression is positively associated with IFNg-producing capacity in HCV-infected subjects [29, 30] . IL-7 has also been shown to augment CD56 bright NK IFN-g production, with heightened effects in NK cells of multiple sclerosis patients [38] . Here, we show that IL-7 enhances NK cell IFN-g release and promotes CD56 bright NK cell IFN-g production. In both HCV and HIV infection, NK cells have been observed to have reduced IFN-g-producing capacity compared with those of UD, including in response to IL-12 and IL-15 [18, 24, [45] [46] [47] . Intriguingly, we demonstrate that IL-7-mediated NK cell IFN-g release and CD56
bright IFN-g production are intact in the setting of HCV and HIV infection. Whereas there were some outliers regarding release of IFN-g by NK cells of HCV-, HIV-, and HCV-HIV-infected subjects, results were compared with UD. At the same time, the unstimulated NK cell granzyme B release was higher in the HCV-infected cohort compared with UD, which is consistent with prior literature and adds support for the concept that NK cells are more prone to cytotoxicity than IFN-g release in patients with chronic HCV infection [23, 24] . NK cell antiviral cytokine release, including IFN-g, is thought to be essential to clear HCV effectively from the infected host [24, 25] . Likewise, NK cells of subjects who naturally control HIV produce greater amounts of IFN-g than progressors and UD in direct ex vivo assays [48] . We observed a positive association between baseline CD56 bright NK cell CD127 expression and IL-7-mediated NK cell IFN-g release in HCV-monoinfected subjects, as well as positive trends between CD56 bright NK cell CD127 expression and IL-7-mediated CD69 up-regulation within UD and HCVmonoinfected subjects. We also found a trend toward a negative correlation between IL-7-mediated NK cell IFN-g release and plasma HCV level in HCV-monoinfected subjects. Together, these data may be consistent with IL-7-induced, CD127-dependent, NK cell IFN-g release, playing a role in host control of HCV.
The present data set confirms previous findings that IL-7 enhances NK cell degranulation [38] , which we demonstrated is intact in chronic HCV and HIV infections. Additionally, we showed that IL-7 promotes NK cell cytolysis of K562 target cells. IL-7 has been shown to mediate NK cell cytolysis via dependency on FasL [40] . Therefore, we speculate that IL-7-mediated NK cell cytotoxicity may work through induction of FasL expression on CD56 bright NK cells. IL-7 also induced TRAIL expression on CD56 bright NK cells, although this was lower in magnitude compared with that induced by IFN-a. There was also no observable IL-7-mediated enhancement of NK cell cytolysis of Huh7.5 cells, a process known to be mediated by TRAIL. In contrast, IFN-a does promote NK cell lysis of Huh7.5 cells [23] . Together, these results suggest that IL-7 does not sufficiently induce CD56
bright NK cell TRAIL-mediated cytolytic activity but rather, promotes NK cell cytolytic activity via FasL up-regulation.
Our data indicate that IL-7-mediated effects on NK cells are impaired in HCV-and HIV-infected subjects. We observed a lack of IL-7-mediated CD56 bright CD69 up-regulation and NK cell granzyme B release in HIV-infected and HIV-HCV-coinfected subjects. The presence of both HCV and HIV infection had a negative effect on IL-7-mediated NK cell cytolysis of K562 target cells. CD56 bright NK cells of HIV-infected subjects displayed little to no IL-7-mediated granzyme B release or FasL up-regulation, which may contribute to the impaired cytolytic response observed in this cohort. Induction of Ki67 expression in the CD56 bright subset by IL-7 was impaired in HCV-, HIV-, and HIV-HCV-coinfected subject samples. The overall inhibition of IL-7-mediated NK cytolytic activity directed at K562 targets may be, in part, attributable to the observed impairment in IL-7-induced cell cycling. By reducing the potential proliferative effect of IL-7 signaling on CD56 bright NK cells, HCV may limit the available pool of NK cells capable of IL-7-mediated cytolytic activity. Alternatively, the observed impairments in IL-7-mediated NK cell activity in the HCV and HIV cohorts may be a result of NK cell exhaustion. In fact, previous findings have shown that CD56 bright NK cells of HCV-infected subjects have enhanced PD-1 [49] .
NK cells can enhance DC maturation, ultimately promoting effective T cell priming, key to the formation of a strong, adaptive immune response [21, 22] . CD56 bright NK cells can also support the maturation of other immune cells, including macrophages, granulocytes, and other lymphocytes [50] . CD56 bright NK cells promote APC maturation via release of TNF-a and IFN-g, which we here observed was enhanced by IL-7. Therefore, IL-7 may promote NK cell-mediated APC maturation via increased release of IFN-g. We saw IL-7-mediated CD69 up-regulation and a trend toward NKG2D enhancement on CD56 bright NK cells, suggesting a potential role for IL-7 in swaying the balance of inhibitory and activating receptor expression. CD56 bright NK cells are known regulators of the adaptive immune response, in part, attributable to their cytokine production [21] , and perhaps IL-7 may help shift the balance to a Th1 response via enhanced NK cell IFN-g release. To understand better the role of IL-7 in this immunoregulatory feature of NK cells, we will need to investigate how IL-7 affects NK cell production of antiviral cytokines and immunosuppressive cytokines (IL-10, TGF-b).
In HIV infection, it is known that T cell IL-7 signaling is impaired at the level of pSTAT-5 [41, 51] , the major transcription factor through which IL-7 signals. Here, we saw a similar pattern of impaired pSTAT-5 induction in CD56 bright NK cells of HCV-, HIV-, and HIV-HCV-coinfected subjects. Whereas CD127 signals through STAT-5, IL-7 also signals through AKT [37] . In contrast to the impaired pSTAT-5 induction, our data support intact, IL-7-mediated pAKT in CD56 bright NK cells of HCV-infected subjects. Inhibition of STAT-5 led to impaired, IL-7-mediated CD56 bright NK cell TRAIL induction, supporting previous work in mice, which indicated that pSTAT-5 is necessary for NK cell proliferation and lytic activity [52] . Inhibition of STAT-5 or AKT impaired IL-7-mediated NK cell IFN-g release, suggesting that although STAT-5 signaling is impaired in HIV and HCV infection, perhaps IL-7-mediated AKT signaling is sufficiently intact to promote NK cell IFN-g release and production. These data shed light on the necessity of further study of IL-7/CD127 signaling in NK cells during conditions of chronic viral infection.
In HCV monoinfection, we observed significantly lower levels of serum IL-7 compared with UD, indicating that HCV infection may reduce levels of available IL-7 [36] . This is consistent with previous findings that have shown reduced levels of serum IL-7 [36] and hepatic IL-7 in chronic HCV-infected subjects [53] and may reflect impaired hepatic IL-7-producing function. In support of the latter, we did observe a trend toward a positive association between serum IL-7 and platelet count in HCVinfected subjects (r = 0.340, P = 0.120). With the rise of use of antiviral therapies for both HCV and HIV, it is of interest to understand better the effects of the removal of viremia on the immune system. Whereas in this present study, we were unable to compare HIV-treatment, naïve subjects with those on therapy, we did attempt to compare HCV-treatment, naïve subjects with those achieving SVR in response to IFN-free therapy. When HCV-infected subjects achieved SVR, CD56
bright NK cell IL-7-mediated pSTAT-5 improved, suggesting that HCV infection likely has a relatively short-term, reversible, negative impact on the IL-7/CD127-mediated NK cell STAT-5 signaling pathway.
These data warrant future study of the effect of removal of HCV on key immune pathways-including IL-7-that influence NK cell function. CD127 haplotype studies have supported the important role of the IL-7Ra in immune cell function. Notably, these haplotype studies include the finding of associations with IL-7Ra polymorphism rs6897932 C/T alleles; whereas the T allele was shown to be protective from multiple sclerosis, the C allele positively associated with the risk of multiple sclerosis [54, 55] . The rs6897932 CC genotype has also been associated with severe liver disease in HIV-HCV-coinfected subjects [56] . The rs6897932 C allele leads to increased formation of sCD127 [56] , and sCD127 has also been shown to be elevated in HIV infection [33] . sCD127 competes with its membrane-bound counterpart for IL-7, interfering with IL-7 signaling [33] . sCD127 may be elevated in HCV and HIV infection, potentially contributing to the observed impairments in IL-7-mediated NK cell activity. Future studies are warranted to elucidate the mechanisms by which these chronic viral infections dampen the effect of IL-7 on NK cells.
Whereas effective, new HCV therapy exists, treatment-resistant populations remain [57] , and HCV eradication altogether worldwide will most likely require a preventative vaccine. Further evaluation of the role of NK cell antiviral effector functions will guide immunotherapeutic strategies to improve viral control and vaccine designs. AUTHORSHIP C.J.J. conceived of the idea, designed the experiments, and performed the experiments and/or interpreted the data. L.K. consented subjects and contributed to data analysis. D.D.A. provided critical comments and contributed to concept and design. All authors contributed to discussion of the results, followed by writing and reviewing the manuscript.
